# A Study in Advanced Solid Tumors

> **NCT01063075** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 34 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Carboplatin
- **DRUG:** 5 - FU

## Key facts

- **NCT ID:** NCT01063075
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2015-05
- **Final completion:** 2015-10
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01063075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01063075, "A Study in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01063075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*